Catalyst Pharmaceuticals ranked fifth on Forbes' 2025 Most Successful Mid-Cap Companies list, showcasing ongoing growth and achievement.
Quiver AI Summary
Catalyst Pharmaceuticals, Inc. has been recognized by Forbes as one of America's Most Successful Mid-Cap Companies for 2025, achieving an impressive fifth place out of 100 companies on the list. This ranking highlights the company's strong performance in earnings growth, sales growth, return on equity, and total stock return over the past five years, with a particular emphasis on the most recent year. Catalyst, which previously ranked fourth as a small-cap company, continues to demonstrate growth under the leadership of CEO Rich Daly. The company is dedicated to improving the lives of patients with rare diseases by developing and commercializing innovative therapies, while also expanding its global presence.
Potential Positives
- Catalyst Pharmaceuticals has been ranked fifth on Forbes' list of America's Most Successful Mid-Cap Companies for 2025, highlighting its strong performance and growth in the biopharmaceutical sector.
- The ranking signifies a positive trajectory in the company's development, moving from fourth place last year among small-cap companies to fifth among mid-cap companies, indicating continued success and scalability.
- This recognition underscores the effectiveness of Catalyst's growth and investment strategy, serving as a positive signal to investors and stakeholders about the company's future potential.
- The inclusion of Catalyst in this prestigious list demonstrates the company's commitment to improving patient care and its ability to deliver life-changing treatments, reinforcing its reputation in the industry.
Potential Negatives
- Despite being ranked fifth on the Forbes list, Catalyst's move from the Small-Cap category to Mid-Cap could indicate a loss of momentum, as they drop one position compared to the previous year's ranking.
- The press release emphasizes reliance on past earnings and growth metrics, which could be viewed as a potential red flag for investors concerned about future performance and market volatility.
FAQ
What recognition did Catalyst Pharmaceuticals receive in 2025?
Catalyst Pharmaceuticals was ranked fifth in Forbes' list of America's Most Successful Mid-Cap Companies for 2025.
How did Catalyst rank last year in Forbes' list?
Last year, Catalyst was ranked fourth in Forbes’ list of America’s Most Successful Small-Cap Companies.
What criteria did Forbes use for this ranking?
The ranking was based on earnings growth, sales growth, return on equity, and total stock return over the last five years.
What is the market capitalization range for companies considered by Forbes?
Forbes considered companies with a market value between $2 billion and $10 billion for its ranking.
What is Catalyst Pharmaceuticals' focus area?
Catalyst Pharmaceuticals focuses on improving the lives of patients with rare diseases through innovative therapies and support services.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CPRX Insider Trading Activity
$CPRX insiders have traded $CPRX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:
- PATRICK J MCENANY has made 0 purchases and 7 sales selling 800,000 shares for an estimated $18,234,161.
- STEVE MILLER (Chief Op. & Scientific Officer) has made 0 purchases and 4 sales selling 200,000 shares for an estimated $4,149,250.
- GARY INGENITO (Chief Med. & Reg. Officer) has made 0 purchases and 4 sales selling 150,000 shares for an estimated $2,882,216.
- CARMEN JEFFREY DEL (Chief Commercial Officer) has made 0 purchases and 2 sales selling 36,058 shares for an estimated $664,309.
- MOLLY HARPER sold 17,500 shares for an estimated $385,000
- DAVID S TIERNEY sold 15,000 shares for an estimated $301,455
- BRIAN ELSBERND (Chief Compliance/Legal Officer) has made 0 purchases and 2 sales selling 13,256 shares for an estimated $286,703.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CPRX Hedge Fund Activity
We have seen 162 institutional investors add shares of $CPRX stock to their portfolio, and 127 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,897,671 shares (-31.7%) from their portfolio in Q3 2024, for an estimated $57,605,699
- JANUS HENDERSON GROUP PLC removed 1,815,450 shares (-83.4%) from their portfolio in Q3 2024, for an estimated $36,091,146
- MORGAN STANLEY added 810,595 shares (+80.0%) to their portfolio in Q3 2024, for an estimated $16,114,628
- POINT72 ASSET MANAGEMENT, L.P. removed 618,296 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $12,291,724
- CITADEL ADVISORS LLC removed 557,683 shares (-95.7%) from their portfolio in Q3 2024, for an estimated $11,086,738
- QUBE RESEARCH & TECHNOLOGIES LTD added 538,506 shares (+418.3%) to their portfolio in Q3 2024, for an estimated $10,705,499
- OPALEYE MANAGEMENT INC. removed 527,500 shares (-82.4%) from their portfolio in Q3 2024, for an estimated $10,486,700
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list.
Last year Catalyst was ranked fourth in Forbes’ list of America’s Most Successful Small-Cap Companies, with this year’s ranking recognizing the company’s continued growth. The top 100 ranking is based on earnings growth, sales growth, return on equity and total stock return for the last five years, with more weight given to the latest year’s data in the ranking. All data is as of November 27, 2024, according to Forbes.
“Being ranked fifth on the Forbes list of America’s Most Successful Mid-Cap Companies for 2025 is a testament to the success of our growth and investment strategy,” said Rich Daly, President and Chief Executive Officer, Catalyst. “Our employees are dedicated to helping patients live healthier lives, and we look forward to continuing our efforts to create value for our employees, patients and shareholders.”
To create the list, Forbes used data from FactSet to screen more than 700 companies with a market value between $2 billion and $10 billion and only considered companies that also had positive sales growth over the past 12 months and a share price of at least $5. Financial institutions, REITs, utilities and limited partnerships were excluded, as were companies that have been public for less than one year.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List.
For more information, please visit Catalyst's website at www.catalystpharma.com .
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.